- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03315689
Safety and Pharmacokinetic Study of ATI-50002 in Subjects With Alopecia Universalis (AU) and Alopecia Totalis (AT)
June 18, 2020 updated by: Aclaris Therapeutics, Inc.
A Randomized, Double-blind, Vehicle-controlled Multicenter Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of ATI-50002 Topical Solution Administered Twice-Daily for 28 Days in Adult Subjects With Alopecia Universalis and Alopecia Totalis With a 12-Month Long-Term Open-Label Extension
The primary objective is to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of ATI-50002 Topical Solution compared to vehicle in subjects with AU and AT.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
This study is designed to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of ATI-50002 Topical Solution in patients with Alopecia Universalis and Alopecia Totalis.
Concentrations of ATI-50002 in the blood and skin will be assessed after 28 days of treatment with ATI-50002 Topical Solution.
Study Type
Interventional
Enrollment (Actual)
11
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
New York
-
New York, New York, United States, 10032
- Aclaris Investigational Site
-
New York, New York, United States, 10075
- Aclaris Investigational Site
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Able to comprehend and willing to sign an Informed Consent Form (ICF).
- Male or non-pregnant, non-nursing female ≥18 years old at the time of informed consent.
- Have a clinical diagnosis of stable, clinically typical, AU or AT.
- Have a duration of the current episode of AU or AT for a minimum of 6 months and a maximum of seven years.
- Be willing and able to follow all study instructions and to attend all study visits.
Exclusion Criteria:
- Females who are nursing, pregnant, or planning to become pregnant for the duration of the study including 30 days after the last application of study medication.
- Patchy alopecia areata, diffuse alopecia areata or a history of an atypical pattern of Alopecia Areata (AA) (e.g., ophiasis, sisaihpo).
- Active skin disease on the scalp (such as psoriasis or seborrheic dermatitis) or a history of skin disease on the scalp that in the opinion of the investigator would interfere with the study assessments of efficacy or safety.
- Active scalp trauma or other condition affecting the scalp that, in the investigator's opinion, may affect the course of AU or AT or interfere with the study conduct or evaluations.
- The presence of a permanent or difficult to remove hairpiece or wig that will, in the opinion of the investigator, interfere with study assessments if not removed at each visit.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: Vehicle
|
Vehicle Topical Solution
|
Experimental: Active
ATI-50002 Topical Solution
|
ATI-50002 Topical Solution
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Double Blind Period: ATI-50002 Levels in Scalp Biopsy (ng/g) - Pharmacodynamic (PD) Population at Day 2 and Day 29
Time Frame: Day 2 - Day 29
|
ATI-50002 levels in scalp biopsies taken at Visits 3 (Day 2) and 7 (Day 29).
|
Day 2 - Day 29
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Open Label Extension: Mean Change From Baseline in the Severity of Alopecia Tool (SALT) Score at Week 52
Time Frame: Baseline - Week 52
|
The Severity of Alopecia Tool (SALT) score is a physician administered scale measuring the amount of scalp without any terminal hair.
Possible scores range from 0 (no scalp hair loss) to 100 (complete scalp hair loss).
A negative change in the SALT score over time represents hair regrowth.
|
Baseline - Week 52
|
Open Label Extension: Mean Change From Baseline in the Severity of Alopecia Tool (SALT) Score at Week 40
Time Frame: Baseline - Week 40
|
The Severity of Alopecia Tool (SALT) score is a physician administered scale measuring the amount of scalp without any terminal hair.
Possible scores range from 0 (no scalp hair loss) to 100 (complete scalp hair loss).
A negative change in the SALT score over time represents hair regrowth.
|
Baseline - Week 40
|
Open Label Extension: Mean Change From Baseline in the Severity of Alopecia Tool (SALT) Score at Week 28
Time Frame: Baseline - Week 28
|
The Severity of Alopecia Tool (SALT) score is a physician administered scale measuring the amount of scalp without any terminal hair.
Possible scores range from 0 (no scalp hair loss) to 100 (complete scalp hair loss).
A negative change in the SALT score over time represents hair regrowth.
|
Baseline - Week 28
|
Open Label Extension: Change From Baseline in Alopecia Density and Extent Score (ALODEX) at Week 28
Time Frame: Baseline - Week 28
|
The Alopecia Density and Extent (ALODEX) score is a measurement of the amount of scalp with terminal hair loss assessed by the investigator.
ALODEX breaks the scalp up into a grid of 1% scalp surface areas and assigns density rating in each area on a 10 point scale of hair loss (0= no hair loss to 10 = complete baldness).
Summation of scores from each 1% scalp surface area provides an overall score which may range from 0 (no scalp hair loss) to 100 (complete baldness).
A negative change in the ALODEX score over time represents hair regrowth.
|
Baseline - Week 28
|
Open Label Extension: Change From Baseline in Alopecia Density and Extent Score (ALODEX) at Week 40
Time Frame: Baseline - Week 40
|
The Alopecia Density and Extent (ALODEX) score is a measurement of the amount of scalp with terminal hair loss assessed by the investigator.
ALODEX breaks the scalp up into a grid of 1% scalp surface areas and assigns density rating in each area on a 10 point scale of hair loss (0= no hair loss to 10 = complete baldness).
Summation of scores from each 1% scalp surface area provides an overall score which may range from 0 (no scalp hair loss) to 100 (complete baldness).
A negative change in the ALODEX score over time represents hair regrowth.
|
Baseline - Week 40
|
Open Label Extension: Change From Baseline in Alopecia Density and Extent Score (ALODEX) at Week 52
Time Frame: Baseline - Week 52
|
The Alopecia Density and Extent (ALODEX) score is a measurement of the amount of scalp with terminal hair loss assessed by the investigator.
ALODEX breaks the scalp up into a grid of 1% scalp surface areas and assigns density rating in each area on a 10 point scale of hair loss (0= no hair loss to 10 = complete baldness).
Summation of scores from each 1% scalp surface area provides an overall score which may range from 0 (no scalp hair loss) to 100 (complete baldness).
A negative change in the ALODEX score over time represents hair regrowth.
|
Baseline - Week 52
|
Open Label Extension: Mean Change in Subject's Eyebrow Assessment (SEA) at Week 28
Time Frame: Week 4 - Week 28
|
The Subject Eyebrow Assessment (SEA) is the subject's assessment of the appearance of eyebrow hair present on the affected eyebrow(s) at a particular point in time.
The SEA is a five-point VRS ranging from "0 - No eyebrow hair", "1 - A little eyebrow hair", "2 - Some eyebrow hair", "3 - Most eyebrow hair", and "4 - Full eyebrow hair" with a recall period of "right now".
A positive change over time represents eyebrow regrowth (better outcome).
|
Week 4 - Week 28
|
Open Label Extension: Mean Change in Subject's Eyebrow Assessment (SEA) at Week 40
Time Frame: Week 4 - Week 40
|
The Subject Eyebrow Assessment (SEA) is the subject's assessment of the appearance of eyebrow hair present on the affected eyebrow(s) at a particular point in time.
The SEA is a five-point VRS ranging from "0 - No eyebrow hair", "1 - A little eyebrow hair", "2 - Some eyebrow hair", "3 - Most eyebrow hair", and "4 - Full eyebrow hair" with a recall period of "right now".
A positive change over time represents eyebrow regrowth (better outcome).
|
Week 4 - Week 40
|
Open Label Extension: Mean Change in Subject's Eyebrow Assessment (SEA) at Week 52
Time Frame: Week 4 - Week 52
|
The Subject Eyebrow Assessment (SEA) is the subject's assessment of the appearance of eyebrow hair present on the affected eyebrow(s) at a particular point in time.
The SEA is a five-point VRS ranging from "0 - No eyebrow hair", "1 - A little eyebrow hair", "2 - Some eyebrow hair", "3 - Most eyebrow hair", and "4 - Full eyebrow hair" with a recall period of "right now".
A positive change over time represents eyebrow regrowth (better outcome).
|
Week 4 - Week 52
|
Open Label Extension: Mean Change in Clinician's Eyebrow Assessment (CEA) at Week 28
Time Frame: Week 4 - Week 28
|
The Clinician's Eyebrow Assessment (CEA) is the investigator's assessment of the appearance of eyebrow hair present on the affected eyebrow(s) at a particular point in time.
The CEA is a five-point VRS ranging from "0 - No eyebrow hair", "1 - A little eyebrow hair", "2 - Some eyebrow hair", "3 - Most eyebrow hair", and "4 - Full eyebrow hair" with a recall period of "right now".
A positive change over time represents eyebrow regrowth (better outcome).
|
Week 4 - Week 28
|
Open Label Extension: Mean Change in Clinician's Eyebrow Assessment (CEA) at Week 40
Time Frame: Week 4 - Week 40
|
The Clinician's Eyebrow Assessment (CEA) is the investigator's assessment of the appearance of eyebrow hair present on the affected eyebrow(s) at a particular point in time.
The CEA is a five-point VRS ranging from "0 - No eyebrow hair", "1 - A little eyebrow hair", "2 - Some eyebrow hair", "3 - Most eyebrow hair", and "4 - Full eyebrow hair" with a recall period of "right now".
A positive change over time represents eyebrow regrowth (better outcome).
|
Week 4 - Week 40
|
Open Label Extension: Mean Change in Clinician's Eyebrow Assessment (CEA) at Week 52
Time Frame: Week 4 - Week 52
|
The Clinician's Eyebrow Assessment (CEA) is the investigator's assessment of the appearance of eyebrow hair present on the affected eyebrow(s) at a particular point in time.
The CEA is a five-point VRS ranging from "0 - No eyebrow hair", "1 - A little eyebrow hair", "2 - Some eyebrow hair", "3 - Most eyebrow hair", and "4 - Full eyebrow hair" with a recall period of "right now".
A positive change over time represents eyebrow regrowth (better outcome).
|
Week 4 - Week 52
|
Open Label Extension: Subject Global Impression of Treatment Satisfaction (SGIS) Week 28
Time Frame: Week 28
|
The Subject Global Impression of Treatment Satisfaction (SGIS) is a 7-point descriptive scale with a recall period of "right now".
The SGIS was completed by subjects during the Open Label period of the study.
Scale response options ranged from "1: Extremely Satisfied", "2: Moderately Satisfied", "3: A little Satisfied", "4: Neither Satisfied or Dissatisfied", "5: A little Dissatisfied", "6: Moderately Dissatisfied", or "7: Extremely Dissatisfied" and are used to capture how satisfied or dissatisfied subjects are with the study medication treatment received for their alopecia areata.
|
Week 28
|
Open Label Extension: Subject Global Impression of Treatment Satisfaction (SGIS) Week 40
Time Frame: Week 40
|
The Subject Global Impression of Treatment Satisfaction (SGIS) is a 7-point descriptive scale with a recall period of "right now".
The SGIS was completed by subjects during the Open Label period of the study.
Scale response options ranged from "1: Extremely Satisfied", "2: Moderately Satisfied", "3: A little Satisfied", "4: Neither Satisfied or Dissatisfied", "5: A little Dissatisfied", "6: Moderately Dissatisfied", or "7: Extremely Dissatisfied" and are used to capture how satisfied or dissatisfied subjects are with the study medication treatment received for their alopecia areata.
|
Week 40
|
Open Label Extension: Subject Global Impression of Treatment Satisfaction (SGIS) Week 52
Time Frame: Week 52
|
The Subject Global Impression of Treatment Satisfaction (SGIS) is a 7-point descriptive scale with a recall period of "right now".
The SGIS was completed by subjects during the Open Label period of the study.
Scale response options ranged from "1: Extremely Satisfied", "2: Moderately Satisfied", "3: A little Satisfied", "4: Neither Satisfied or Dissatisfied", "5: A little Dissatisfied", "6: Moderately Dissatisfied", or "7: Extremely Dissatisfied" and are used to capture how satisfied or dissatisfied subjects are with the study medication treatment received for their alopecia areata.
|
Week 52
|
Open Label Extension: Severity of Alopecia Tool (SALT) Scores, Relative Percent Regrowth (%) at Week 24 From Baseline
Time Frame: Baseline - Week 24
|
The Severity of Alopecia Tool (SALT) score is a physician administered scale measuring the amount of scalp without any terminal hair assessed by the investigator.
A positive percent change over time represents hair regrowth (better outcome).
|
Baseline - Week 24
|
Open Label Extension: Severity of Alopecia Tool (SALT Scores), Relative Percent Regrowth (%) at Week 40 From Baseline
Time Frame: Baseline - Week 40
|
The Severity of Alopecia Tool (SALT) score is a physician administered scale measuring the amount of scalp without any terminal hair assessed by the investigator.
A positive percent change over time represents hair regrowth (better outcome).
|
Baseline - Week 40
|
Open Label Extension: The Severity of Alopecia Tool (SALT) Scores, Relative Percent Regrowth (%) at Week 52 From Baseline
Time Frame: Baseline - Week 52
|
The Severity of Alopecia Tool (SALT) score is a physician administered scale measuring the amount of scalp without any terminal hair assessed by the investigator.
A positive percent change over time represents hair regrowth (better outcome).
|
Baseline - Week 52
|
Open Label Extension: The Alopecia Density and Extent (ALODEX) Scores, Relative Percent Regrowth (%) at 24 Weeks
Time Frame: Baseline - Week 24
|
The Alopecia Density and Extent (ALODEX) score is a measurement of the amount of scalp with terminal hair loss assessed by the investigator.
ALODEX breaks the scalp up into a grid of 1% scalp surface areas and assigns density rating in each area on a 10 point scale of hair loss (0= no hair loss to 10 = complete baldness).
Summation of scores from each 1% scalp surface area provides an overall score which may range from 0 (no scalp hair loss) to 100 (complete baldness).
A positive percent change over time represents hair regrowth (better outcome).
|
Baseline - Week 24
|
Open Label Extension: The Alopecia Density and Extent (ALODEX) Scores, Relative Percent Regrowth (%) at 40 Weeks
Time Frame: Baseline - Week 40
|
The Alopecia Density and Extent (ALODEX) score is a measurement of the amount of scalp with terminal hair loss assessed by the investigator at Baseline, Week 4, Week 8, Week 12, Week 16, Week 20, and Week 24.
ALODEX breaks the scalp up into a grid of 1% scalp surface areas and assigns density rating in each area on a 10 point scale of hair loss (0= no hair loss to 10 = complete baldness).
Summation of scores from each 1% scalp surface area provides an overall score which may range from 0 (no scalp hair loss) to 100 (complete baldness).
A positive percent change over time represents hair regrowth (better outcome).
|
Baseline - Week 40
|
Open Label Extension: The Alopecia Density and Extent (ALODEX) Scores, Relative Percent Regrowth (%) at 52 Weeks
Time Frame: Baseline - Week 52
|
The Alopecia Density and Extent (ALODEX) score is a measurement of the amount of scalp with terminal hair loss assessed by the investigator.
ALODEX breaks the scalp up into a grid of 1% scalp surface areas and assigns density rating in each area on a 10 point scale of hair loss (0= no hair loss to 10 = complete baldness).
Summation of scores from each 1% scalp surface area provides an overall score which may range from 0 (no scalp hair loss) to 100 (complete baldness).
A positive percent change over time represents hair regrowth (better outcome).
|
Baseline - Week 52
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
December 14, 2017
Primary Completion (Actual)
June 20, 2019
Study Completion (Actual)
June 20, 2019
Study Registration Dates
First Submitted
October 17, 2017
First Submitted That Met QC Criteria
October 17, 2017
First Posted (Actual)
October 20, 2017
Study Record Updates
Last Update Posted (Actual)
July 2, 2020
Last Update Submitted That Met QC Criteria
June 18, 2020
Last Verified
June 1, 2020
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- ATI-50002-AA-202
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
No
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Alopecia Totalis (AT)
-
Yale UniversityCompletedAlopecia Areata (AA) | Alopecia Totalis (AT) | Alopecia Universalis (AU)United States
-
Julian M. Mackay-WigganWithdrawnAlopecia Totalis/Universalis
-
Siriraj HospitalCompletedRecalcitrant Alopecia Totalis | Recalcitrant Alopecia UniversalisThailand
-
Throne Biotechnologies Inc.RecruitingAlopecia Areata | Alopecia Totalis | Alopecia UniversalisUnited States
-
Jinnah HospitalCompletedAlopecia Areata | Alopecia Totalis | Alopecia UniversalisPakistan
-
Yale UniversityCompletedAlopecia Areata | Alopecia Totalis | Alopecia UniversalisUnited States
-
King Saud UniversitySaudi Society of Dermatology and Dermatologic surgeryCompletedAlopecia Totalis | Alopecia Universalis | Ophiasic AlopeciaSaudi Arabia
-
EquilliumEquillium AUS Pty LtdActive, not recruitingAlopecia | Alopecia Areata | Alopecia Totalis | Alopecia UniversalisAustralia, New Zealand
-
Aclaris Therapeutics, Inc.TerminatedAlopecia Areata | Alopecia Totalis | Alopecia UniversalisUnited States
-
EquilliumWithdrawnAlopecia Areata | Alopecia Totalis | Alopecia Universalis
Clinical Trials on ATI-50002
-
Aclaris Therapeutics, Inc.TerminatedAlopecia AreataUnited States
-
Aclaris Therapeutics, Inc.Completed
-
Aclaris Therapeutics, Inc.CompletedAndrogenetic AlopeciaUnited States
-
Aclaris Therapeutics, Inc.CompletedAlopecia Areata | Alopecia Totalis | Alopecia UniversalisUnited States
-
Autonomic Technologies, Inc.CompletedHigh Frequency, High Disability MigraineBelgium, Denmark, Spain
-
Autonomic Technologies, Inc.UnknownChronic Cluster HeadacheUnited States
-
ARYx TherapeuticsCompletedAtrial FibrillationUnited States, Canada
-
Aclaris Therapeutics, Inc.TerminatedCryopyrin-Associated Periodic SyndromeUnited States
-
Aclaris Therapeutics, Inc.CompletedAtopic DermatitisUnited States
-
Antios Therapeutics, IncCompletedHepatitis B, ChronicCanada, Moldova, Republic of, Ukraine